(192) LafB-mRNA LNP: Advancing S. pneumoniae Vaccination
Introduction: Streptococcus pneumoniae is the leading cause of pneumonia, sepsis, and meningitis in infants and the elderly (1). Current vaccines based on capsular polysaccharides only protect against 20% of serotypes (2). LafB, a newly identified and highly conserved S. pneumoniae protein, could be an effective antigen alternative (3), while lipid nanoparticles (LNPs) stand as the gold standard for nucleic acid delivery (4). In this study we developed two messenger RNA (mRNA)-LNP formulations encoding different LafB antigens (LafB1 and LafB2) as a promising vaccine platform against S. pneumoniae infection.
Learning Objectives:
Formulate lipid nanoparticles that effectively associate and deliver antigen-codifying mRNA.
Evaluate the potential of LafB antigens to elicit immune responses against S. pneumoniae in vivo.
Study the suitability of the mRNA-LNP technology as advanced vaccines for bacterial infections.
Noemi Stefania Csaba – Professor, PI, University of Santiago de Compostela; María José Alonso Fernández – Group Lider, Full Professor, University of Santiago de Compostela; Jean-Claude Sirard – Research director, team leader, Institut Pasteur de Lille / Inserm; Anne Rogel – Associate Professor, University of Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille; Lisa Sachet – PhD student, Institut Pasteur de Lille; Youlia Serikova – Senior Manager, RNA Research, Quantoom Biosciences; Grégory Godefroi – Scientist, RNA Research, Quantoom Biosciences; Jan-Willem Veening – Group leader, full professor, University of Lausanne; Florian Patrick Bock – Post-doctoral researcher, University of Lausanne
.jpg "Julia Baena Paz, MSc photo")
